Levoride Tablet contains Levosulpiride 25 mg, a selective dopamine D2 receptor antagonist primarily used in the treatment of gastrointestinal motility disorders and certain psychiatric conditions. Levosulpiride exerts prokinetic effects by enhancing gastric emptying and improving esophageal motility, making it effective in managing symptoms associated with functional dyspepsia, gastroesophageal reflux disease (GERD), and irritable bowel syndrome (IBS). Additionally, its central dopaminergic antagonist properties contribute to its utility in treating schizophrenia, depression, and anxiety disorders, particularly when accompanied by gastrointestinal symptoms. Levoride is well-absorbed orally, with a relatively rapid onset of action. It is generally prescribed at a dose of 25 mg, with adjustments based on clinical response and tolerability. Common adverse effects include mild extrapyramidal symptoms, drowsiness, and gastrointestinal disturbances such as nausea or diarrhea. Caution is advised in patients with a history of prolactin-dependent tumors, epilepsy, or renal impairment. Levoride should not be combined with other dopamine antagonists without medical supervision. Regular monitoring by a healthcare professional is recommended to assess therapeutic efficacy and detect any adverse reactions. This medication should be used under strict medical guidance to ensure optimal outcomes.